Abstract
Objective:To investigate the literature on genetic abnormalities of DNA in blood and saliva from OSCC patients, to report diagnostic accuracy, and to address the possibilities for a diagnostic or recurrence monitoring test based on circulating tumor DNA (ctDNA).Methods and materials:A systematic search was performed in PubMed for articles published between 2013 and 2021. The search terms used were “circulating tumor DNA in oral squamous cell carcinoma”.Results:We found eleven relevant studies, of which four (36.36%) prospective population studies were included. In all studies ctDNA were used as biomarker in OSCC. Two studies were looked into ctDNA somatic and methylated DNA mutations in OSCC. Another study found 90% of the ctDNA alteration and one study identifi ed PD-L1gene, which plays an important role in primary cancers based on tumour size, as well as disease-specific survival. Conclusion: This study concluded that the use of ctDNA as biomarkers in OSCC clinical routine will help to establish consistent strategies for the early detection of cancer lesions enable early prevention and support the development of targeted therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
